Heterozygous germline BRCA2 mutations predispose to breast, ovarian, pancreatic and other types of cancer. The presence of a pathogenic mutation in patients or their family members warrants close surveillance or prophylactic surgery. Besides clearly pathogenic mutations, variants leading only to a single amino acid substitution are often identified. The influence of such variants on cancer risk is often unknown, making their presence a major clinical problem. When genetic methods are insufficient to classify these variants, functional assays with various cellular models are performed. We developed and applied a new syngeneic model of human cancer cells to test all variants of unknown significance in exon 18 identified by genetic testing of high-risk cancer patients in the Czech Republic, via introduction of constructs containing each of these variants into the wild-type allele of BRCA2-heterozygous DLD1 cells (BRCA2wt/Δex11). We found unaffected DNA repair function of BRCA2 in cell lines BRCA27997G>C/Δex11, BRCA28111C>T/Δex11, BRCA28149G>T/Δex11, BRCA28182G>A/Δex11, and BRCA28182G>T/Δex11, whereas the cell line BRCA28168A>G/Δex11 and the nonsense mutation carrying line BRCA28305G>T/Δex11 did affect protein function. Targeting the BRCA2 wild-type allele with a construct carrying the variant c.7988A> G resulted in incorporation exclusively into the already defective allele in all viable clones, strongly suggesting a detrimental phenotype. Our model thus offers a valuable tool for the functional evaluation of unclassified variants in the BRCA2 gene and provides a stable and distributable cellular resource for further research.

b Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

c Department of Gastroenterology and Hepatology Institute of Clinical and Experimental Medicine Prague Czech Republic

Center for Experimental Medicine Institute of Clinical and Experimental Medicine Prague Czech Republic

Center for Experimental Medicine Institute of Clinical and Experimental Medicine Prague Czech Republic c Department of Gastroenterology and Hepatology Institute of Clinical and Experimental Medicine Prague Czech Republic

Department of Internal Medicine Philipps University of Marburg Marburg Germany

000      

00000naa a2200000 a 4500

001      

bmc20025966

003      

CZ-PrNML

005      

20201222155544.0

007      

ta

008      

201125s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1080/15384047.2018.1550566 $2 doi

035    __

$a (PubMed)30638113

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Heczkova, Marie $u a Center for Experimental Medicine , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

245    10

$a Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing / $c M. Heczkova, E. Machackova, P. Macinga, E. Gallmeier, M. Cahova, J. Spicak, M. Jirsa, L. Foretova, T. Hucl,

520    9_

$a Heterozygous germline BRCA2 mutations predispose to breast, ovarian, pancreatic and other types of cancer. The presence of a pathogenic mutation in patients or their family members warrants close surveillance or prophylactic surgery. Besides clearly pathogenic mutations, variants leading only to a single amino acid substitution are often identified. The influence of such variants on cancer risk is often unknown, making their presence a major clinical problem. When genetic methods are insufficient to classify these variants, functional assays with various cellular models are performed. We developed and applied a new syngeneic model of human cancer cells to test all variants of unknown significance in exon 18 identified by genetic testing of high-risk cancer patients in the Czech Republic, via introduction of constructs containing each of these variants into the wild-type allele of BRCA2-heterozygous DLD1 cells (BRCA2wt/Δex11). We found unaffected DNA repair function of BRCA2 in cell lines BRCA27997G>C/Δex11, BRCA28111C>T/Δex11, BRCA28149G>T/Δex11, BRCA28182G>A/Δex11, and BRCA28182G>T/Δex11, whereas the cell line BRCA28168A>G/Δex11 and the nonsense mutation carrying line BRCA28305G>T/Δex11 did affect protein function. Targeting the BRCA2 wild-type allele with a construct carrying the variant c.7988A> G resulted in incorporation exclusively into the already defective allele in all viable clones, strongly suggesting a detrimental phenotype. Our model thus offers a valuable tool for the functional evaluation of unclassified variants in the BRCA2 gene and provides a stable and distributable cellular resource for further research.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a protein BRCA2 $x genetika $7 D024682

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a mutační analýza DNA $x metody $7 D004252

650    _2

$a exony $x genetika $7 D005091

650    _2

$a studie proveditelnosti $7 D005240

650    _2

$a ženské pohlaví $7 D005260

650    12

$a genetická predispozice k nemoci $7 D020022

650    _2

$a genetické testování $x metody $7 D005820

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a Markovovy řetězce $7 D008390

650    _2

$a anamnéza $7 D008487

650    _2

$a lidé středního věku $7 D008875

650    12

$a biologické modely $7 D008954

650    _2

$a mutace $7 D009154

650    _2

$a nádory $x diagnóza $x genetika $7 D009369

650    _2

$a hodnocení rizik $x metody $7 D018570

651    _2

$a Česká republika $7 D018153

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Machackova, Eva $u b Department of Cancer Epidemiology and Genetics , Masaryk Memorial Cancer Institute , Brno , Czech Republic.

700    1_

$a Macinga, Peter $u c Department of Gastroenterology and Hepatology , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

700    1_

$a Gallmeier, Eike $u d Department of Internal Medicine , Philipps University of Marburg , Marburg , Germany.

700    1_

$a Cahova, Monika $u a Center for Experimental Medicine , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

700    1_

$a Spicak, Julius $u c Department of Gastroenterology and Hepatology , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

700    1_

$a Jirsa, Milan $u a Center for Experimental Medicine , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

700    1_

$a Foretova, Lenka $u b Department of Cancer Epidemiology and Genetics , Masaryk Memorial Cancer Institute , Brno , Czech Republic.

700    1_

$a Hucl, Tomas $u a Center for Experimental Medicine , Institute of Clinical and Experimental Medicine , Prague , Czech Republic. c Department of Gastroenterology and Hepatology , Institute of Clinical and Experimental Medicine , Prague , Czech Republic.

773    0_

$w MED00173145 $t Cancer biology & therapy $x 1555-8576 $g Roč. 20, č. 5 (2019), s. 633-641

856    41

$u https://pubmed.ncbi.nlm.nih.gov/30638113 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20201222155540 $b ABA008

999    __

$a ok $b bmc $g 1600111 $s 1116652

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 20 $c 5 $d 633-641 $e 20190113 $i 1555-8576 $m Cancer biology & therapy $n Cancer Biol Ther $x MED00173145

LZP    __

$a Pubmed-20201125